动图学研究的终点是减少样本大小,促进儿童肺动脉高血压的药物开发
Haihao Sun1, Norman Stockbridge1, D Dunbar Ivy2
1Office of the Commissioner, U.S. Food and Drug Administration (FDA), Silver Spring, MD.
The Journal of pediatrics
|November 3, 2024
概括
动图学准确地测量了儿科肺动脉高血压 (PAH) 的身体活动和心率变化. 这些测量显示出比6分钟步行距离更高的灵敏度来检测疾病的严重程度.
科学领域:
- 儿科心脏病学 儿科心脏病学
- 进行心肺运动测试.
- 生物医学工程 生物医学工程
背景情况:
- 儿科肺动脉高血压 (PAH) 需要临床试验的敏感结果措施.
- 6分钟的步行距离 (6MWD) 是儿科PAH研究中常见的,但潜在的不敏感的终点.
- 动图提供了一种非侵入性的方法来评估身体活动和心率变化.
研究的目的:
- 评估动力图的可行性,以测量儿科PAH的体力活动 (pA) 和心率变化 (HRV).
- 为了比较由动图学衍生的终点与6分钟步行距离 (6MWD) 的性能.
- 评估动图测量在区分疾病严重程度方面的敏感性 (例如,巴拿马功能分类).
主要方法:
- 一项前性,多中心,非干预性研究,涉及儿科PAH患者和健康对照组.
- 使用Actiheart和Fitbit Charge 2设备记录pA和心率数据.
- 分析对比了PAH患者和对照者之间以及功能分类组之间的动图pA和HRV,以及6MWD.
主要成果:
- 动图学证明了可行性,具有很高的坚持率 (90%的Actiheart,98%的Fitbit).
- 与健康对照组相比,患有PAH的儿童的每日pA (~36%) 和HRV (~18%) 显著降低.
- 在功能分类III和II中,动图测量趋势较低,而6MWD显示的差异很小;样本大小模拟表明HRV需要的受试者比pA或6MWD少.
结论:
- 与6MWD相比,Actigraphy是儿童PAH的可行和可能更敏感的结果测量方法.
- 来自动图的心率变化 (HRV) 可能会增强其实用性,并提高检测疾病严重程度差异的灵敏度.
- 动图学,特别是HRV,在临床试验中有望改善对儿科PAH的评估.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
135
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
142
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
142